Report
Valens Research

TMO - Embedded Expectations Analysis - 2022 03 08

Thermo Fisher Scientific Inc. (TMO) currently trades in line with corporate but above historical averages relative to Uniform earnings, with a 24.4x Uniform P/E (Fwd. V/E').

At these levels, markets are pricing in expectations for Uniform ROA to compress to 32%, accompanied by 7% Uniform asset growth.

Meanwhile, analysts project Uniform ROA to compress to 30%, accompanied by 58% Uniform asset growth.

If sustained going forward, these levels would imply significant potential equity upside for the firm. That said, analyst expectations are driven largely by the PPD acquisition in 2021, and this growth is likely not sustainable in the long run.

Meanwhile, the firm's most recent earnings call suggests management may have concerns about profitability, growth, and margins.
Underlying
Thermo Fisher Scientific Inc.

Thermo Fisher Scientific is engaged in serving science. The company's segments include: Life Sciences Solutions, which provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments, which provides instruments, consumables, software and services that are used for a range of applications in the laboratory, on the production line and in the field; and Specialty Diagnostics, which provides diagnostic test kits, reagents, culture media, instruments and associated products for customers in healthcare, clinical, pharmaceutical, industrial, and food safety laboratories.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch